OncoCyte (OCX) News Today $2.81 -0.11 (-3.77%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period OncoCyte Co. (NASDAQ:OCX) Sees Large Growth in Short InterestOncoCyte Co. (NASDAQ:OCX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 373,800 shares, an increase of 22.4% from the February 28th total of 305,500 shares. Approximately 2.5% of the company's stock are sold short. Based on an average daily volume of 89,700 shares, the short-interest ratio is currently 4.2 days.April 4 at 10:50 AM | marketbeat.comOncoCyte Co. (NASDAQ:OCX) Short Interest UpdateApril 4 at 1:57 AM | americanbankingnews.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 8:45 AM | globenewswire.comStockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)April 2 at 1:23 AM | americanbankingnews.comOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comStockNews.com started coverage on shares of OncoCyte in a research note on Monday. They set a "sell" rating on the stock.April 1 at 11:17 PM | marketbeat.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1 at 3:13 AM | markets.businessinsider.comOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Pura Vida Investments LLCPura Vida Investments LLC boosted its stake in OncoCyte Co. (NASDAQ:OCX - Free Report) by 32.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 654,451 shares of the company's stock afterMarch 31, 2025 | marketbeat.comOncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at Lake Street CapitalLake Street Capital began coverage on shares of OncoCyte in a research note on Friday. They issued a "buy" rating and a $5.00 price objective for the company.March 29, 2025 | marketbeat.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comNeedham & Company LLC Reiterates "Buy" Rating for OncoCyte (NASDAQ:OCX)March 27, 2025 | americanbankingnews.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comOncoCyte's (OCX) Equal Weight Rating Reiterated at StephensStephens restated an "equal weight" rating and issued a $4.00 target price on shares of OncoCyte in a research note on Tuesday.March 26, 2025 | marketbeat.comOncoCyte's (OCX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $4.25 target price on shares of OncoCyte in a research note on Tuesday.March 26, 2025 | marketbeat.comOncocyte Corp. Reports Q4 2024 Results with $1.5 Million in Revenue and Significant Clinical Advancements in Transplant TestingMarch 26, 2025 | nasdaq.comOncoCyte (NASDAQ:OCX) Given "Equal Weight" Rating at StephensMarch 26, 2025 | americanbankingnews.comOncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comOncoCyte (NASDAQ:OCX) Announces Earnings ResultsOncoCyte (NASDAQ:OCX - Get Free Report) announced its earnings results on Monday. The company reported $0.48 earnings per share for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%.March 25, 2025 | marketbeat.comOncocyte targets $20M in recurring revenue from 20 transplant centers by 2025March 24, 2025 | msn.comOncoCyte Corporation (OCX) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comOncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsMarch 24, 2025 | globenewswire.comOncoCyte Corporation (OCX): Among Top Insider Purchases Last MonthMarch 14, 2025 | msn.comOncoCyte (NASDAQ:OCX) Trading Up 14.7% - Should You Buy?OncoCyte (NASDAQ:OCX) Trading Up 14.7% - Here's WhyMarch 5, 2025 | marketbeat.comOncoCyte Corporation (OCX): Among Penny Stocks with Insider Buying in 2025March 4, 2025 | msn.comOncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.comOncocyte corp CFO buys $200,000 in stockFebruary 12, 2025 | msn.comAndrea S. James Buys 97,561 Shares of OncoCyte Co. (NASDAQ:OCX) StockFebruary 12, 2025 | insidertrades.comOncocyte corp's Patrick Smith acquires shares worth $2.2 millionFebruary 11, 2025 | msn.comBroadwood Partners acquires OncoCyte shares worth $9.24 millionFebruary 11, 2025 | msn.comOncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 11, 2025 | globenewswire.comOncocyte Prices $29.1 Million Equity OfferingFebruary 10, 2025 | globenewswire.comOncocyte corp investor Patrick Smith buys $1,839 in sharesFebruary 5, 2025 | msn.comInsider Stock Buying Reaches US$508.4k On OncoCyteJanuary 31, 2025 | finance.yahoo.comOncoCyte stock hits 52-week low at $1.92 amid market challengesJanuary 22, 2025 | msn.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 5,669 Shares of StockJanuary 16, 2025 | insidertrades.comOncoCyte appoints Billings as consulting CMOJanuary 8, 2025 | markets.businessinsider.comOncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerJanuary 8, 2025 | globenewswire.comOncocyte Expands Market Opportunity for VitaGraft™ KidneyJanuary 6, 2025 | globenewswire.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 90,219 Shares of StockDecember 31, 2024 | insidertrades.comAndrew Arno Purchases 12,500 Shares of OncoCyte Co. (NASDAQ:OCX) StockDecember 27, 2024 | insidertrades.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) CFO Purchases 20,000 Shares of StockDecember 10, 2024 | insidertrades.comOncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsDecember 9, 2024 | globenewswire.comOncoCyte Corporation: Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyDecember 5, 2024 | finanznachrichten.deOncoCyte announces publication of DetermaCNI assay dataDecember 4, 2024 | markets.businessinsider.comOncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyDecember 4, 2024 | globenewswire.comOncoCyte announces VitaGraft data published in journalDecember 4, 2024 | markets.businessinsider.comOncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study AffirmsDecember 2, 2024 | globenewswire.comOncoCyte Corp Reports Q3 2024 Earnings and Strategic UpdatesNovember 13, 2024 | markets.businessinsider.comOncoCyte’s Strategic Advances and Financial Prudence Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.com Remove Ads Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Media Mentions By Week OCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼0.420.61▲Average Medical News Sentiment OCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼112▲OCX Articles Average Week Remove Ads Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvectis Pharma News Monopar Therapeutics News Korro Bio News INmune Bio News Tevogen Bio News Voyager Therapeutics News Eledon Pharmaceuticals News Inhibrx News AC Immune News DiaMedica Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredThe bigger story behind the recent market pullbackNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.